Analysis Of Income And Expense [Abstract]

ABIONYX Pharma - Filing #2816648

Concept 2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
675,000 EUR
Material income and expense [abstract]
Research and development expense
3 838 EUR
1 698 EUR
Finance income (cost)
130,000 EUR
1 082 EUR
Selling, general and administrative expense [abstract]
Selling, general and administrative expense
2 336 EUR
1 270 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
48,000 EUR
48,000 EUR
0 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
5 759 EUR
1 891 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.